FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587433062> ?p ?o ?g. }

• W2587433062 abstract "Three classes of inhaler medications are used to manage chronic obstructive pulmonary disease (COPD): long-acting beta-agonists (LABA), long-acting muscarinic antagonists (LAMA), and inhaled corticosteroids (ICS). When two classes of medications are required, LAMA plus LABA (LAMA+LABA) and LABA plus ICS (LABA+ICS) are often selected because these combinations can be administered via a single medication device. The previous Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidance recommended LABA+ICS as the first-line treatment for managing stable COPD in high-risk people of categories C and D. However, the updated GOLD 2017 guidance recommends LAMA+LABA over LABA+ICS.To compare the benefits and harms of LAMA+LABA versus LABA+ICS for treatment of people with stable COPD.We performed an electronic search of the Cochrane Airways Group Specialised Register (2 February 2016), ClinicalTrials.gov (4 June 2016), and the World Health Organization Clinical Trials Search Portal (4 June 2016), followed by a handsearch (5 June 2016). Two review authors screened and scrutinised the selected articles.We included individual randomised controlled trials, parallel-group trials, and cross-over trials comparing LAMA+LABA and LABA+ICS for stable COPD. The minimum accepted trial duration was one month and trials should have been conducted in an outpatient setting.Two review authors independently extracted data and evaluated risk of bias. We resolved any discrepancies through discussion. We analysed dichotomous data as odds ratios (OR), and continuous data as mean differences (MD), with 95% confidence interval (CI) using Review Manager 5. Exacerbations were measured by counting the number of people experiencing one or more exacerbation.We included 11 studies comprising 9839 participants in our quantitative analysis. Most studies included people with moderate to severe COPD, without recent exacerbations. One pharmaceutical sponsored trial that included only people with recent exacerbations was the largest study and accounted for 37% of participants. All but one study were sponsored by pharmaceutical companies, thus we rated them as having a high risk of 'other bias'. The unsponsored study was at high risk of performance and detection bias, and possible selective reporting.Five studies recruited GOLD Category B participants, one study recruited Category D participants, two studies recruited Category A/B participants, and three studies recruited participants regardless of category. Follow-up ranged from 6 to 52 weeks.Compared to the LABA+ICS arm, the results for the pooled primary outcomes for the LAMA+LABA arm were as follows: exacerbations, OR 0.82 (95% CI 0.70 to 0.96, P = 0.01, I2 = 17%, low quality evidence); serious adverse events (SAE), OR 0.91 (95% CI 0.79 to 1.05, P = 0.18, I2 = 0, moderate quality evidence); St. George's Respiratory Questionnaire (SGRQ) total score change from the baseline, MD -1.22 (95% CI -2.52 to 0.07, P = 0.06, I2 = 71%, low quality evidence); and trough forced expiratory volume in one second (FEV1) change from the baseline, MD 0.08 L (95% CI 0.06 to 0.09, P < 0.0001, I2 = 50%, moderate quality evidence). Compared to the LABA+ICS arm, the results for the pooled secondary outcomes for the LAMA+LABA arm were as follows: pneumonia, OR 0.57 (95% CI 0.42 to 0.79, P = 0.0006, I2 = 0%, low quality evidence); all-cause death, OR 1.01 (95% CI 0.61 to 1.67, P = 0.88, I2 = 0%, low quality evidence); and SGRQ total score change from the baseline of 4 points or greater (the minimal clinically important difference for the SGRQ is 4 points), OR 1.25 (95% CI 1.09 to 1.44, P = 0.002, I2 = 0%, moderate quality evidence).For the treatment of COPD, LAMA+LABA has fewer exacerbations, a larger improvement of FEV1, a lower risk of pneumonia, and more frequent improvement in quality of life as measured by an increase over 4 units or more of the SGRQ. These data were supported by low or moderate quality evidence generated from mainly participants with moderate to severe COPD in heterogeneous trials with an observation period of less than one year. Our findings support the recently updated GOLD guidance." @default.
• W2587433062 created "2017-02-17" @default.
• W2587433062 creator A5015083168 @default.
• W2587433062 creator A5022959950 @default.
• W2587433062 creator A5046995514 @default.
• W2587433062 creator A5054367448 @default.
• W2587433062 creator A5059987560 @default.
• W2587433062 creator A5065856181 @default.
• W2587433062 creator A5068530089 @default.
• W2587433062 date "2017-02-10" @default.
• W2587433062 modified "2023-10-12" @default.
• W2587433062 title "Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)" @default.
• W2587433062 cites W137920967 @default.
• W2587433062 cites W1496026319 @default.
• W2587433062 cites W1553966959 @default.
• W2587433062 cites W1637753636 @default.
• W2587433062 cites W1841491799 @default.
• W2587433062 cites W1861036421 @default.
• W2587433062 cites W1987881697 @default.
• W2587433062 cites W2002645597 @default.
• W2587433062 cites W2006528231 @default.
• W2587433062 cites W2012931218 @default.
• W2587433062 cites W2014426593 @default.
• W2587433062 cites W2020661357 @default.
• W2587433062 cites W2023136584 @default.
• W2587433062 cites W2031165494 @default.
• W2587433062 cites W2037067833 @default.
• W2587433062 cites W2043491932 @default.
• W2587433062 cites W2045616259 @default.
• W2587433062 cites W2049344199 @default.
• W2587433062 cites W2051460383 @default.
• W2587433062 cites W2055423609 @default.
• W2587433062 cites W2062778089 @default.
• W2587433062 cites W2067545437 @default.
• W2587433062 cites W2076224944 @default.
• W2587433062 cites W2093321679 @default.
• W2587433062 cites W2100204036 @default.
• W2587433062 cites W2115758036 @default.
• W2587433062 cites W2116505643 @default.
• W2587433062 cites W2125435699 @default.
• W2587433062 cites W2135563121 @default.
• W2587433062 cites W2146120854 @default.
• W2587433062 cites W2150978030 @default.
• W2587433062 cites W2153715784 @default.
• W2587433062 cites W2156098321 @default.
• W2587433062 cites W2158978379 @default.
• W2587433062 cites W2163317499 @default.
• W2587433062 cites W2165010366 @default.
• W2587433062 cites W2267101752 @default.
• W2587433062 cites W2316606215 @default.
• W2587433062 cites W2346284690 @default.
• W2587433062 cites W2365138737 @default.
• W2587433062 cites W246286872 @default.
• W2587433062 cites W2496257167 @default.
• W2587433062 cites W2587433062 @default.
• W2587433062 cites W2759566626 @default.
• W2587433062 cites W4294215472 @default.
• W2587433062 cites W1981381921 @default.
• W2587433062 doi "https://doi.org/10.1002/14651858.cd012066.pub2" @default.
• W2587433062 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6464543" @default.
• W2587433062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28185242" @default.
• W2587433062 hasPublicationYear "2017" @default.
• W2587433062 type Work @default.
• W2587433062 sameAs 2587433062 @default.
• W2587433062 citedByCount "51" @default.
• W2587433062 countsByYear W25874330622017 @default.
• W2587433062 countsByYear W25874330622018 @default.
• W2587433062 countsByYear W25874330622019 @default.
• W2587433062 countsByYear W25874330622020 @default.
• W2587433062 countsByYear W25874330622021 @default.
• W2587433062 countsByYear W25874330622022 @default.
• W2587433062 countsByYear W25874330622023 @default.
• W2587433062 crossrefType "journal-article" @default.
• W2587433062 hasAuthorship W2587433062A5015083168 @default.
• W2587433062 hasAuthorship W2587433062A5022959950 @default.
• W2587433062 hasAuthorship W2587433062A5046995514 @default.
• W2587433062 hasAuthorship W2587433062A5054367448 @default.
• W2587433062 hasAuthorship W2587433062A5059987560 @default.
• W2587433062 hasAuthorship W2587433062A5065856181 @default.
• W2587433062 hasAuthorship W2587433062A5068530089 @default.
• W2587433062 hasBestOaLocation W25874330621 @default.
• W2587433062 hasConcept C126322002 @default.
• W2587433062 hasConcept C156957248 @default.
• W2587433062 hasConcept C170493617 @default.
• W2587433062 hasConcept C2776042228 @default.
• W2587433062 hasConcept C2776723954 @default.
• W2587433062 hasConcept C2776780178 @default.
• W2587433062 hasConcept C2776804153 @default.
• W2587433062 hasConcept C2780261241 @default.
• W2587433062 hasConcept C2780911369 @default.
• W2587433062 hasConcept C33789571 @default.
• W2587433062 hasConcept C535046627 @default.
• W2587433062 hasConcept C71924100 @default.
• W2587433062 hasConceptScore W2587433062C126322002 @default.
• W2587433062 hasConceptScore W2587433062C156957248 @default.
• W2587433062 hasConceptScore W2587433062C170493617 @default.
• W2587433062 hasConceptScore W2587433062C2776042228 @default.
• W2587433062 hasConceptScore W2587433062C2776723954 @default.
• W2587433062 hasConceptScore W2587433062C2776780178 @default.
• W2587433062 hasConceptScore W2587433062C2776804153 @default.

• next